Sonia Vasquez
Medical · El Centro, CANPI 1619184009
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 30.1% of the total. Reporting peaked in 2024 at $1,116 and has fallen 55.0% since, to $502 in 2025.
Across 185 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$537
- Regeneron Healthcare Solutions, Inc.$428
- Ironwood Pharmaceuticals, Inc$388
- Madrigal Pharmaceuticals$384
- Intercept Pharmaceuticals, Inc.$237
- plus $940 from 14 others
What the payments were for
- Food & beverage$4,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,171 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 55 | $165,400 |
| LinzessLinaclotide | 194 | $159,132 |
| CreonLipase/Protease/Amylase | 44 | $138,358 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $71,150 |
| ZenpepLipase/Protease/Amylase | 16 | $57,834 |
| MovantikNaloxegol Oxalate | 125 | $54,192 |
| TrulancePlecanatide | 35 | $34,172 |
| Dexlansoprazole DrDexlansoprazole | 85 | $32,336 |
| Sucralfate | 243 | $22,811 |
| Lubiprostone | 117 | $15,962 |
| Ursodiol | 79 | $8,796 |
| CholestyramineCholestyramine (With Sugar) | 129 | $8,180 |
| Omeprazole | 700 | $6,909 |
| Lactulose | 156 | $6,878 |
| Pantoprazole Sodium | 660 | $6,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $537 | $297,490238 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,256 | $199,57290 claims |
| Redhill Biopharma Inc.Movantik | $57 | $54,192125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.
Other medical in El Centro
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.